Spyre Therapeutics, Inc. (SYRE)
80.97
+0.86
(+1.07%)
USD |
NASDAQ |
Oct 07, 13:26
Spyre Therapeutics Enterprise Value : 6.056B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 6.056B |
| October 05, 2026 | 7.166B |
| October 02, 2026 | 7.208B |
| October 01, 2026 | 6.921B |
| September 30, 2026 | 6.841B |
| September 29, 2026 | 6.462B |
| September 28, 2026 | 6.556B |
| September 25, 2026 | 6.547B |
| September 24, 2026 | 6.671B |
| September 23, 2026 | 6.766B |
| September 22, 2026 | 7.100B |
| September 21, 2026 | 7.106B |
| September 18, 2026 | 6.949B |
| September 17, 2026 | 7.163B |
| September 16, 2026 | 7.030B |
| September 15, 2026 | 7.011B |
| September 14, 2026 | 6.997B |
| September 11, 2026 | 6.980B |
| September 10, 2026 | 6.813B |
| September 09, 2026 | 6.656B |
| September 08, 2026 | 6.996B |
| September 04, 2026 | 6.837B |
| September 03, 2026 | 6.685B |
| September 02, 2026 | 6.667B |
| September 01, 2026 | 6.795B |
| Date | Value |
|---|---|
| August 31, 2026 | 6.868B |
| August 28, 2026 | 6.959B |
| August 27, 2026 | 7.245B |
| August 26, 2026 | 7.244B |
| August 25, 2026 | 8.456B |
| August 24, 2026 | 8.393B |
| August 21, 2026 | 8.379B |
| August 20, 2026 | 8.494B |
| August 19, 2026 | 8.593B |
| August 18, 2026 | 8.496B |
| August 17, 2026 | 8.213B |
| August 14, 2026 | 8.127B |
| August 13, 2026 | 7.970B |
| August 12, 2026 | 8.168B |
| August 11, 2026 | 8.049B |
| August 10, 2026 | 8.277B |
| August 07, 2026 | 8.240B |
| August 06, 2026 | 8.109B |
| August 05, 2026 | 8.191B |
| August 04, 2026 | 8.243B |
| August 03, 2026 | 7.361B |
| July 31, 2026 | 7.660B |
| July 30, 2026 | 7.940B |
| July 29, 2026 | 7.620B |
| July 28, 2026 | 7.804B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 535.56B |
| Incyte Corp. | 18.16B |
| SELLAS Life Sciences Group, Inc. | 2.152B |
| Relay Therapeutics, Inc. | 3.215B |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.20M |
| Total Expenses (Quarterly) | 36.20M |
| EPS Diluted (Quarterly) | -0.4272 |
| Earnings Yield | -2.69% |
| Normalized Earnings Yield | -2.781 |